Ardsley Advisory Partners LP Myovant Sciences Ltd. Transaction History

Ardsley Advisory Partners LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$13.8 - $27.62 $139,380 - $278,962	-10,100 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$14.05 - $22.6 $139,095 - $223,740	-9,900 Reduced 49.5%	10,100 $142,000
Q2 2020 Aug 14, 2020	BUY	$7.34 - $20.84 $146,800 - $416,800	20,000 New	20,000 $412,000
Q1 2018 May 15, 2018	SELL	$12.46 - $21.32 $1.25 Million - $2.13 Million	-100,000 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$11.37 - $16.4 $1.14 Million - $1.64 Million	100,000	100,000 $1.27 Million

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Ardsley Advisory Partners LP, based on Form 13F filings with the SEC.

Stay updated on Ardsley Advisory Partners LP with notifications on news.